Global Humira Market Overview:
Humira (Adalimumab), is an anti-TNF drug used for the treatment of ulcerative colitis, rheumatoid arthritis, Crohn’s disease psoriatic arthritis, etc. When a TNF alpha binds to TBF alpha receptors in an inflammatory response to autoimmune disease, lowers the chances of inflammatory response. Further, increasing prevalence of diseases like arthritis, psoriasis diseases and high investment in R & D of patent drugs and biosimilars are anticipated to propel the market growth.
- Increasing Prevalence of Chronic Diseases such as Crohn's Disease
- Sedentary Lifestyle of Consumers Leading to Growth in Medical Conditions like Arthritis
- Well Structured Regulatory Framework by the Government for the Humira Drug
- Increasing Number of Product Pipeline of Humira Drug
- High Cost Factor of Humiria Drug is hampering the Market Growth
- Focus of Market Players on the Development of Humira Biosimilars for the Treatment of Rheumatoid arthritis and Psoriasis
- Increasing Investment in Healthcare Infrastructure
- Side Effects associated with the Humira Drugs among Some Patients
The global Humira market is consolidated with very few players trying to compete with one another on the basis of price. Most of the leading players are focused on the development of Humira biosimilars for the treatment.
Some of the key players profiled in the report are AbbVie Inc.(United States), Eisai Co., Ltd. (Japan), Cadila Pharmaceuticals (India), Torrent Pharmaceuticals Ltd. (India), Amgen Inc. (United States) and Boehringer Ingelheim International GmbH (Germany). Considering Market by Sales Channel, the sub-segment i.e. OTC Drugs will boost the Humira market.
June 2018, AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA (generic name: adalimumab [recombinant], “HUMIRA”), a fully human anti-TNF- monoclonal antibody formulation, was launched after being listed in the National Health Insurance reimbursement price list on June 15, 2018 .
In September 2017, AbbVie GK company won a patent litigation battle with Amgen. Drugmakers AbbVie Inc. and Amgen Inc. reached a patent-dispute settlement requiring Amgen to wait until 2023 to start selling a lower-priced copy of the world’s top-selling drug, AbbVie’s arthritis treatment Humira, in the United States.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Humira market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Humira market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical Companies, Industry Associations, Potential Investors, Marketing & Consulting Firms, Government and Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.